Logo
Logo

About Bendamustine Hydrochloride API

Product
  • Therapeutic CategoryAnti-Cancer/ Oncology

  • CAS Number

    3543-75-7

  • API Technology

    Synthetic

  • Dose Form

    Injectable

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF, Brazil DMF, EUDMF, Korea DMF

Mechanism of Action

Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.

Indication

TREANDA for Injection is an alkylating drug indicated for treatment of patients with:

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
  • Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximabcontaining regimen.

Related APIs

Abiraterone Acetate

Anti-Cancer/ Oncology

arrow

Adagrasib

Anti-Cancer/ Oncology

arrow

Apalutamide (Amorphous & Form B)

Anti-Cancer/ Oncology

arrow

Azacitidine

Anti-Cancer/ Oncology

arrow

Bendamustine Hydrochloride

Anti-Cancer/ Oncology

arrow

Bortezomib

Anti-Cancer/ Oncology

arrow

Cabazitaxel

Anti-Cancer/ Oncology

arrow

Cabozantinib HCl

Anti-Cancer/ Oncology

arrow

Cabozantinib S-Malate

Anti-Cancer/ Oncology

arrow

Capecitabine

Anti-Cancer/ Oncology

arrow

Carfilzomib

Anti-Cancer/ Oncology

arrow

Darolutamide

Anti-Cancer/ Oncology

arrow

Dasatinib (Monohydrate)

Anti-Cancer/ Oncology

arrow

Decitabine

Anti-Cancer/ Oncology

arrow

Deucravacitinib

Anti-Cancer/ Oncology

arrow

Enzalutamide

Anti-Cancer/ Oncology

arrow

Eribulin (Available For Selected Markets)

Anti-Cancer/ Oncology

arrow

Fosaprepitant

Anti-Cancer/ Oncology

arrow

Fruquintinib

Anti-Cancer/ Oncology

arrow

Gemcitabine Hydrochloride

Anti-Cancer/ Oncology

arrow

Granisteron

Anti-Cancer/ Oncology

arrow

Lenalidomide (Form A)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate ( MIBK Solvate)

Anti-Cancer/ Oncology

arrow

Lenvatinib Mesylate (Form-C)

Anti-Cancer/ Oncology

arrow

Lomustine

Anti-Cancer/ Oncology

arrow

Midostaurin

Anti-Cancer/ Oncology

arrow

Nilotinib Hydrochloride Monohydrate (Form B)

Anti-Cancer/ Oncology

arrow

Niraparib Tosylate

Anti-Cancer/ Oncology

arrow

Olaparib (Form A)

Anti-Cancer/ Oncology

arrow

Palbociclib

Anti-Cancer/ Oncology

arrow

Pazopanib

Anti-Cancer/ Oncology

arrow

Pemetrexed Disodium Heptahydrate

Anti-Cancer/ Oncology

arrow

Pirtobrutinib

Anti-Cancer/ Oncology

arrow

Pomalidomide

Anti-Cancer/ Oncology

arrow

Relugolix

Anti-Cancer/ Oncology

arrow

Ripretinib

Anti-Cancer/ Oncology

arrow

Ritlecitinib

Anti-Cancer/ Oncology

arrow

Ruxolitinib Phosphate

Anti-Cancer/ Oncology

arrow

Tucatinib

Anti-Cancer/ Oncology

arrow

Venetoclax

Anti-Cancer/ Oncology

arrow

Zanubrutinib

Anti-Cancer/ Oncology

arrow

Zoledronic Acid

Anti-Cancer/ Oncology

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.